“Consisting Of” Creates Closed Group and Provides Avenue to Avoid Infringement

Shire Development v. Watson Pharma (Fed. Cir. 2017) [16-1785-opinion-2-8-2017-11] In a short opinion, the Federal Circuit has reversed a lower court infringement claim — holding instead that Watson’s generic product does not infringe. In U.S. Patent law, it is an act of infringement to file an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration […]